Published in Drug Metab Dispos on December 01, 1999
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther (2006) 2.23
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab (2008) 2.06
Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis (2009) 1.63
Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol (2006) 1.30
Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol (2011) 1.30
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol (2007) 1.25
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol (2002) 1.23
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS (2011) 1.23
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother (2010) 1.19
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet (2013) 1.16
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother (2009) 1.14
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr (2009) 1.10
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother (2011) 1.06
P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother (2004) 1.06
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc (2013) 1.05
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther (2010) 1.04
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genomics (2012) 1.04
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol (2008) 1.01
Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J (2009) 1.01
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med (2008) 0.99
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Malar J (2014) 0.96
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics (2012) 0.93
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis (2011) 0.93
Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries. Drug Metab Dispos (2010) 0.90
Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Springerplus (2012) 0.89
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol (2009) 0.89
High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos (2007) 0.89
Molecular characterization of CYP2B6 substrates. Curr Drug Metab (2008) 0.88
Protein adducts as prospective biomarkers of nevirapine toxicity. Chem Res Toxicol (2010) 0.88
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J (2015) 0.87
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malar J (2015) 0.86
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J Acquir Immune Defic Syndr (2010) 0.86
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 0.86
Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur J Clin Pharmacol (2008) 0.85
Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens. AIDS Res Ther (2010) 0.85
Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol (2009) 0.85
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics (2011) 0.84
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. Br J Clin Pharmacol (2006) 0.83
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol (2012) 0.83
Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Antimicrob Agents Chemother (2013) 0.82
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. Br J Clin Pharmacol (2009) 0.82
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission. J Infect Dis (2013) 0.81
Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc (2008) 0.81
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol (2012) 0.80
Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life. BMC Pediatr (2015) 0.80
HIV associated nephropathy: a treatable condition. Sex Transm Infect (2001) 0.79
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol (2010) 0.79
Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study. AIDS Res Ther (2015) 0.79
Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B (2016) 0.78
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother (2015) 0.78
Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline. Antimicrob Agents Chemother (2014) 0.77
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. Int J Tuberc Lung Dis (2013) 0.77
The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans. Drug Metab Dispos (2012) 0.77
Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors. Futur HIV Ther (2008) 0.77
Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine. Br J Pharmacol (2015) 0.76
Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers. BMC Pharmacol Toxicol (2017) 0.75
Transcriptional Regulation of CYP2B6 Expression by Hepatocyte Nuclear Factor 3β in Human Liver Cells. PLoS One (2016) 0.75
Individualization of antiretroviral therapy - Pharmacogenomic aspect. Indian J Med Res (2015) 0.75
Drug-phytochemical interactions. Inflammopharmacology (2003) 0.75
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients. Indian J Med Res (2013) 0.75
The pregnane X receptor in tuberculosis therapeutics. Expert Opin Drug Metab Toxicol (2015) 0.75
Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Res Ther (2017) 0.75
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother (2016) 0.75
Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data? PLoS One (2016) 0.75
Purification and properties of the light-activated cyclic nucleotide phosphodiesterase of rod outer segments. J Biol Chem (1975) 2.72
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol (1992) 2.41
Motion: the long and short of it. Spat Vis (1989) 2.27
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
Improved non-parametric statistical methods for the estimation of Michaelis-Menten kinetic parameters by the direct linear plot. Biochem J (1977) 1.75
Enzymatic degradation of heme. Oxygenative cleavage requiring cytochrome P-450. Biochemistry (1972) 1.71
The motion aftereffect. Trends Cogn Sci (1998) 1.63
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Regulation of cyclic nucleotide concentrations in photoreceptors: an ATP-dependent stimulation of cyclic nucleotide phosphodiesterase by light. Proc Natl Acad Sci U S A (1973) 1.58
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys (1996) 1.56
Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol (1994) 1.49
Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 1.47
Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology (2004) 1.38
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther (1994) 1.36
A link between rhodopsin and disc membrane cyclic nucleotide phosphodiesterase. Action spectrum and sensitivity to illumination. Biochemistry (1975) 1.31
The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther (1992) 1.30
Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols. J Lab Clin Med (1973) 1.27
Evaluation of distribution-free confidence limits for enzyme kinetic parameters. J Theor Biol (1978) 1.27
A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res (1999) 1.26
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther (1992) 1.23
Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci (1998) 1.22
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther (1994) 1.22
Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos (1996) 1.21
Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos (1996) 1.18
Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos (1996) 1.17
Absolute configurations of the four warfarin alcohols. J Med Chem (1972) 1.15
The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther (1986) 1.14
Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther (1978) 1.12
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res (2002) 1.12
Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest (1970) 1.11
Carbamazepine as an anticonvulsant: a pilot study. Neurology (1974) 1.07
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos (1996) 1.06
Activation of photoreceptor disk membrane phosphodiesterase by light and ATP. Adv Cyclic Nucleotide Res (1975) 1.06
Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res (2005) 1.05
Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos (1989) 1.05
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol (1998) 1.05
A simultaneous shift in apparent direction: further evidence for a "distribution-shift" model of direction coding. Q J Exp Psychol (1980) 1.04
Monitoring of free valproic acid levels? Ther Drug Monit (1980) 1.04
The movement aftereffect and a distribution-shift model for coding the direction of visual movement. Perception (1980) 1.02
The effect of oxidized glutathione on NADPH inhibition of glucose-6-phosphate dehydrogenase is indirect. Biochem J (1985) 1.01
A temperature-sensitive change in the energy of activation of hormone-stimulated hepatic adenylyl cyclase. Proc Natl Acad Sci U S A (1973) 1.01
Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry (1999) 1.01
Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest (1980) 1.01
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res (1999) 0.99
Drug interactions with valproic acid. Drugs (1982) 0.98
Isolation of cyclic AMP and cyclic GMP by thin-layer chromatography. Application to assay of adenylate cyclase, guanylate cyclase, and cyclic nucleotide phosphodiesterase. Anal Biochem (1974) 0.98
The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci (1971) 0.98
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol (1994) 0.98
Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4'-dimethylbiphenyl by cytochrome P450: relationship between distance of methyl groups and masking of the intrinsic isotope effect. Biochemistry (1997) 0.97
Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther (1975) 0.97
Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther (1989) 0.97
The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther (1987) 0.96
Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia (1994) 0.96
Metabolic fate of phenprocoumon in humans. J Pharm Sci (1985) 0.96
Theory for the observed isotope effects from enzymatic systems that form multiple products via branched reaction pathways: cytochrome P-450. Biochemistry (1989) 0.96
Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther (1980) 0.96
Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res (2001) 0.95
Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther (2010) 0.95
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos (1997) 0.95
Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther (1996) 0.95
Rationale for monitoring free drug levels. Clin Pharmacokinet (1984) 0.94
Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos (1996) 0.94
Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry (1998) 0.94
Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia (1979) 0.93
Effects of luminance and contrast on direction of ambiguous apparent motion. Perception (1985) 0.93
Basic pharmacokinetics. Ther Drug Monit (1986) 0.93
Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol. Epilepsy Res (1992) 0.93
Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci (1976) 0.92
Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent. J Med Chem (1990) 0.92
Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther (2012) 0.91
Efficacy and toxicity of the solvent polyethylene glycol 400 in monkey model. Epilepsia (1979) 0.91
Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys (1999) 0.91
Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry (1998) 0.91
Biologic activity of purified cotton bract extracts in man and guinea pig. Environ Health Perspect (1986) 0.91
Racemates versus enantiomers in drug development: dogmatism or pragmatism? Chirality (1990) 0.90
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther (1987) 0.90
Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther (1985) 0.89
Time-dependent kinetics I: Exponential autoinduction of carbamazepine in monkeys. J Pharm Sci (1977) 0.89
Studies on nicotinamide adenine dinucleotide phosphate reductase of spinach chloroplasts. J Biol Chem (1972) 0.89
Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther (1985) 0.89
Zonisamide in epilepsy: a pilot study. Epilepsia (1985) 0.89
Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos (1983) 0.88
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther (1997) 0.88
Structure of warfarin in solution. J Med Chem (1977) 0.88
The subunit structure of beef heart cytochrome oxidase. Biochem Biophys Res Commun (1971) 0.88
Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos (1989) 0.88
Isotope effect studies on the mechanism of the cytochrome P-450IIA1-catalyzed formation of delta 6-testosterone from testosterone. Drug Metab Dispos (1991) 0.88
Proceedings: Light regulation of adenosine 3',5' cyclic monophosphate levels in vertebrate photoreceptors. Exp Eye Res (1974) 0.87
Induction effect of phenobarbital on the carbamazepine to carbamazepine-10, 11-epoxide pathway in rhesus monkeys. J Pharmacol Exp Ther (1981) 0.87
Warfarin-stereochemical aspects of its metabolism by rat liver microsomes. Biochem Pharmacol (1976) 0.87
Stereochemical biotransformation of warfarin as a probe of the homogeneity and mechanism of microsomal hydroxylases. Biochem Pharmacol (1977) 0.87
Studies on the mechanism of aromatase and other cytochrome P450 mediated deformylation reactions. J Steroid Biochem Mol Biol (1993) 0.87
Phenobarbital--valporic acid interaction. Clin Pharmacol Ther (1980) 0.87
Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res (1993) 0.87
Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. Biochemistry (1989) 0.86
Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone. J Pharm Sci (1984) 0.86
A kinetic method for the determination of the multiple forms of microsomal cytochrome P-450. Biochem Pharmacol (1977) 0.86